The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome - A Prospective Study

Sci Rep. 2016 Jun 27:6:28431. doi: 10.1038/srep28431.

Abstract

ANGPTL8/betatrophin is a recently discovered hormone, which mainly synthesized and secreted by liver and adipose tissue, playing a critical role in pancreatic beta cell proliferation. Previous studies have suggested that serum ANGPTL8/betatrophin levels are associated with obesity and diabetes mellitus. Here, we evaluated the prospective association between ANGPTL8/betatrophin and the metabolic syndrome from a community-based cohort of 153 adults without metabolic syndrome. After 3.5-year follow-up, we observed an inverse correlation between the baseline ANGPTL8/betatrophin levels and the incidence of metabolic syndrome, even after multivariate adjustments. In receiver operating characteristic analysis, the area underneath the curve for ANGPTL8/betatrophin was 0.70 in males and 0.86 in females, and the optimal cut-off values were 23.9 ng/mL and 31.1 ng/mL, respectively. This article suggests that ANGPTL8/betatrophin might be useful in predicting newly-onset metabolic syndrome and its progression in clinical setting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiopoietin-Like Protein 8
  • Angiopoietin-like Proteins / blood*
  • Area Under Curve
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / diagnosis*
  • Middle Aged
  • Odds Ratio
  • Peptide Hormones / blood*
  • Prospective Studies
  • ROC Curve
  • Risk Factors
  • Sensitivity and Specificity

Substances

  • ANGPTL8 protein, human
  • Angiopoietin-Like Protein 8
  • Angiopoietin-like Proteins
  • Peptide Hormones